Neurocrine Q4 INGREZZA sales $500M (+25% YoY); FY 2024 guidance $2.1-$2.2B

NEUROCRINE BIOSCIENCES INC

2023-FY EPS reported $2.47 revenue$1,887,100,000

Q4 GAAP net income $147.7M ($1.44 diluted EPS) vs $89M ($0.88) in Q4 2022; non-GAAP EPS $1.54.
Full-year 2023 INGREZZA net product sales $1.84B (+29% YoY); total revenue $1.89B.
FY 2024 INGREZZA sales guidance $2.1–$2.2B; GAAP R&D $645–$675M, SG&A $930–$950M.
Patent litigation resolved; generic INGREZZA entry no earlier than March 2038.
Crinecerfont FDA submission for congenital adrenal hyperplasia expected Q2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NEUROCRINE BIOSCIENCES INC updated its the fourth quarter and fiscal year ended December 31, 2023 guidance (reaffirmed).

Period: the fourth quarter and fiscal year ended December 31, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On February 7, 2024, Neurocrine Biosciences, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023.

View on SEC.gov

38 earnings releases filed in the last 30 days. Browse all earnings releases →

NEUROCRINE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000914475-24-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.